Lead all aspects of customer insights generation, product revenue forecasting, KPI development & tracking, as well as commercial & sales operations in support of the launch of new treatments for pediatric oncology patients

Led a global team of market research & analytics professionals in support of Pfizer's portfolio of inline and novel pipeline / gene therapy products for rare diseases including: TTR Amyloidosis, Sickle Cell Disease, Duchenne Muscular Dystrophy, Hemophilia, and Acromegaly. Delivered high quality insights and organizational impact based on primary & secondary research, product forecasting, and data science / machine learning.

Led one direct report and cross-functional analytics colleagues to maximize the growth of Pfizer's first-in-class CDK4/6 inhibitor IBRANCE (palbociclib) for the treatment of metastatic breast cancer in the US. Responsible for optimizing commercial strategies & tactics via insight generation and secondary data analytics, generating revenue forecasts, and tracking market/brand intelligence.

Led professional and consumer market research to understand market dynamics, identify customer insights, and drive launch success of IBRANCE (palbociclib) in ER+ / HER2- advanced breast cancer in the US. Responsible for launch tracking, short & long range revenue forecasts, and lifecycle opportunity assessments.

Led primary research, forecasting, and performance tracking in support of the launch of first-in-class ALK+ NSCLC agent, Xalkori (crizotinib), in the US. Previously supported the growth of Pfizer's Renal Cell Carcinoma franchise (Sutent, Torisel, & Inlyta), Sutent in Gastrointestinal Stromal Tumor, and the launch of Sutent in Pancreatic Neuroendocrine Tumor

Managed primary market research and secondary data analysis for various US brand teams including: Sutent, Viagra, Relpax, Zmax, Arthrotec, Caverject, depo-subQ provera 104, Estring, Medrol franchise, Dilantin, and Revatio.

Responsible for primary market research and secondary data analysis for WW and US Diversified Products teams.

Engaged small and large pharma and biotech clients for strategic consulting, including portfolio decision analysis, market opportunity assessment, and product lifecycle management.

Conducted secondary research and interviews with key opinion leaders in support of syndicated research reports for CNS markets, including epilepsy, bipolar disorder, and major depression.